“Thymic carcinoma is a rare cancer with poor prognosis after recurrence, and there is a need for new treatment options. We are working to obtain approval so that Tecentriq that demonstrated favourable ...

“Thymic carcinoma is a rare cancer with poor prognosis after recurrence, and there is a need for new treatment options. We are working to obtain approval so that Tecentriq that demonstrated favourable ...

A proteomics-driven 24-protein classifier improves the differentiation of thyroid adenoma and carcinoma, retrospectively and ...

ILC accounts for 10–15% of breast cancers and often goes undetected. Learn about its characteristics, treatments, and future ...

Lung Squamous cell carcinoma (LSCC) represents the second most common non-small cell lung cancer. Although studies identified ...

Credit: NIAID In the early 1960s, Professor Jaques Miller discovered the essential role of the thymus in our immune systems while working as a PhD student at The Institute of Cancer Research in London ...

as well as continuing refinements in molecular pathology and imaging. The increased personalisation of cancer therapy, introduction of multidisciplinary treatment approaches, and widespread adoption ...

The U.S. Food and Drug Administration has approved the humanized monoclonal antibody Zynyz (retifanlimab-dlwr) as the first first-line treatment for advanced anal cancer. Zynyz is a programmed ...

Complete Pathologic Response reported in 2 patients in the Third Cohort with cutaneous squamous cell carcinoma, complementing results in prior cohort Marlborough, Massachusetts--(Newsfile Corp ...

The Centre for Molecular Pathology is a collaborative initiative between The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, aiming to identify the molecular mechanisms that ...